Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HF 8 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HF 8 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
AMINOSYN-HF 8% vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-HF 8% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue repair in patients unable to tolerate oral intake.
Travasol 2.75% with electrolytes in dextrose 20% provides amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of fluid and electrolyte balance. Dextrose stimulates insulin release, promoting cellular uptake of glucose and amino acids, while electrolytes help maintain osmolality and acid-base balance.
1-2 g/kg/day intravenously as total parenteral nutrition, typically administered as a continuous infusion over 24 hours.
Intravenous infusion: Typical adult dose is 1-2 L/day of TRAVASOL 2.75% with 20% dextrose, administered as continuous infusion via central line. Rate should be adjusted based on metabolic and fluid needs.
None Documented
None Documented
Not applicable as amino acids are rapidly cleared; terminal half-life of infused amino acids is approximately 10-30 minutes.
Not applicable; TRAVASOL is a mixture of dextrose, electrolytes, and amino acids with no defined terminal elimination half-life as individual components are metabolized or excreted rapidly.
Renal: >90% as amino acids and metabolites; fecal: <5%.
Renal: 100% as free water, electrolytes, and dextrose metabolites; no biliary or fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution